Gadavist (contrast agent)

2023: Product Announcement

On August 8, 2023, Fresenius Kabi announced the release of Gadobutrol, a universal contrast agent substitute for Gadavist, which is used in magnetic resonance imaging (MRI) procedures.

The basis of Gadavist is gadolinium, a chemical element that in its simple form is a soft rare earth metal of silver-white color. It is used as part of paramagnetic contrast agents in MRI. The drug is given intravenously and accumulates in areas with increased blood supply, for example, in malignant formations.

Fresenius Kabi announces release of gadobutrol

Gadobutrol for injection is a gadolinium-based contrast agent designed for use with MRI. The product is available in single dose vials of 2 mL, 7.5 mL, 10 mL and 15 mL. The substance does not contain preservatives. Gadobutrol can be used to identify and visualize areas with impaired blood-brain barrier and/or abnormal central nervous system vascularization in adults and children, including full-term newborns. The drug is also suitable for assessing the presence and prevalence of breast malignancies, detecting renal artery disease in adults and children, assessing myocardial perfusion, etc.

As contraindications, hypersensitivity to injections of gadobutrol in the history is called. The most common adverse reactions (frequency ≥ 0.5%) are headache, nausea and dizziness. The drug can be used in pregnancy only if imaging is extremely necessary and cannot be delayed.

Fresenius Kabi is excited to introduce Gadobutrol as the newest addition to our radiology portfolio, expanding the range of cost-effective contrast agent options for hospitals and clinics, "said John Ducker, President and CEO of the company.[1]

Notes